As the OECD continues to evaluate and work on refining its transfer pricing guidelines regarding several BEPS initiatives, ktMINE CEO, David Jarczyk, and Director of Operations, John Wiora, explore the topic of ‘information asymmetry’. The article, “Challenging asymmetric data, leveraging public data”, concludes that by accessing publicly available global data, taxpayers and their consultants protect their analyses by
Apple and Qualcomm’s royalty rates dispute continues to escalate. The following series of events have been pivotal in the licensing relationship. Our lead analyst, Megan Rourke, explored the initial complaints in the post, Apple and Qualcomm Battle Over Patent Royalties. See details below Save
As more and more individuals undergo genetic testing to discover their DNA ancestry and genetic health, Ancestry’s repository of DNA information, and the repositories of other companies in the direct-to-consumer genetic testing industry, will continue to grow. This raises some privacy concerns about the use of DNA information stored in these companies’ databases. DNA Testing
Aggregated royalty rate data demonstrates that royalty payment agreement bases are becoming more diverse. In addition, several trends around the industries making royalty rate transactions indicate changes in the marketplace.
For companies investing in, or considering investing in, the DNA at-home testing kit market, there is both high value and high risk. We see this by the growing demand in DNA ancestry, and with the high number of DNA genealogy patent infringement lawsuits.
Apple has stopped paying the chipset patent royalties they previously agreed to, leading to a 40% drop in Qualcomm profits. Apple filed suit, and Qualcomm is fighting back.
As regulations change, the amount of global intercompany agreement data that is publicly available has increased dramatically. To keep up, have robust transfer pricing analyses, and defend future analyses, you’ll need to utilize it.
Using wearable heart rate technology patents, company transactions, and news as an example, ktMINE demonstrates how to predict if your invention can be well monetized.
Samsung’s IP in pharma, particularly in biosimilars and biotechnology, as well as the Samsung joint venture with Merck, demonstrates that they are poised to disturb the drug market.
This new product feature adds intellectual property (IP) connections to the Profiles Application. With our data linking technology, we have made connections between companies and IP information that reveal insights into valuable corporate relationships. What would typically take hundreds of hours of research, users can now quickly find a list of companies and IP details